ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America
ICU Medical (NASDAQ: ICUI) and Otsuka Pharmaceutical Factory (OPF) have completed the formation of Otsuka ICU Medical LLC, a joint venture aimed at strengthening IV solutions manufacturing and innovation in North America. The partnership creates one of the largest global IV solutions manufacturing networks with combined production of 1.4 billion annual units.
The joint venture combines OPF's expertise and global manufacturing scale across 16 IV solutions production sites in Asia with ICU Medical's North American production facility in Austin, Texas. The collaboration will enhance supply chain resiliency and introduce new PVC-free technologies to the North American market. ICU Medical will provide commercial services for seamless operations.
ICU Medical (NASDAQ: ICUI) e Otsuka Pharmaceutical Factory (OPF) hanno completato la creazione di Otsuka ICU Medical LLC, una joint venture volta a rafforzare la produzione e l'innovazione di soluzioni endovenose (IV) in Nord America. La partnership dà vita a una delle reti di produzione di soluzioni IV più grandi al mondo, con una produzione combinata di 1,4 miliardi di unità annuali.
La joint venture unisce l'esperienza di OPF e la sua scala produttiva globale, con 16 siti di produzione di soluzioni IV in Asia, alla struttura produttiva di ICU Medical in Nord America, situata ad Austin, Texas. Questa collaborazione migliorerà la resilienza della catena di approvvigionamento e introdurrà nuove tecnologie prive di PVC nel mercato nordamericano. ICU Medical fornirà servizi commerciali per garantire operazioni fluide.
ICU Medical (NASDAQ: ICUI) y Otsuka Pharmaceutical Factory (OPF) han completado la formación de Otsuka ICU Medical LLC, una empresa conjunta destinada a fortalecer la fabricación e innovación de soluciones intravenosas (IV) en Norteamérica. La alianza crea una de las redes de fabricación de soluciones IV más grandes del mundo, con una producción combinada de 1.4 mil millones de unidades anuales.
La empresa conjunta combina la experiencia de OPF y su escala global de fabricación en 16 sitios de producción de soluciones IV en Asia con la planta de producción de ICU Medical en Austin, Texas, Norteamérica. La colaboración mejorará la resiliencia de la cadena de suministro e introducirá nuevas tecnologías libres de PVC en el mercado norteamericano. ICU Medical proporcionará servicios comerciales para operaciones sin contratiempos.
ICU Medical(NASDAQ: ICUI)과 Otsuka Pharmaceutical Factory(OPF)는 북미에서 정맥주사(IV) 솔루션 제조 및 혁신을 강화하기 위한 합작법인 Otsuka ICU Medical LLC 설립을 완료했습니다. 이번 파트너십으로 연간 14억 단위의 통합 생산을 갖춘 세계 최대 규모의 IV 솔루션 제조 네트워크 중 하나가 탄생했습니다.
합작법인은 아시아에 위치한 16개의 IV 솔루션 생산 시설에서 OPF의 전문성과 글로벌 제조 규모를 ICU Medical의 텍사스 오스틴 북미 생산 시설과 결합합니다. 이번 협력은 공급망 복원력을 강화하고 북미 시장에 새로운 PVC 프리 기술을 도입할 예정입니다. ICU Medical은 원활한 운영을 위한 상업 서비스를 제공합니다.
ICU Medical (NASDAQ : ICUI) et Otsuka Pharmaceutical Factory (OPF) ont finalisé la création de Otsuka ICU Medical LLC, une coentreprise visant à renforcer la fabrication et l'innovation des solutions intraveineuses (IV) en Amérique du Nord. Ce partenariat crée l'un des plus grands réseaux mondiaux de fabrication de solutions IV, avec une production combinée de 1,4 milliard d'unités par an.
La coentreprise associe l'expertise d'OPF et son échelle mondiale de production répartie sur 16 sites de production de solutions IV en Asie à l'installation de production nord-américaine d'ICU Medical à Austin, Texas. Cette collaboration améliorera la résilience de la chaîne d'approvisionnement et introduira de nouvelles technologies sans PVC sur le marché nord-américain. ICU Medical fournira des services commerciaux pour assurer un fonctionnement fluide.
ICU Medical (NASDAQ: ICUI) und Otsuka Pharmaceutical Factory (OPF) haben die Gründung von Otsuka ICU Medical LLC abgeschlossen, einem Joint Venture zur Stärkung der Herstellung und Innovation von IV-Lösungen in Nordamerika. Die Partnerschaft schafft eines der größten globalen Produktionsnetzwerke für IV-Lösungen mit einer kombinierten Jahresproduktion von 1,4 Milliarden Einheiten.
Das Joint Venture verbindet OPFs Expertise und globale Fertigungskapazitäten an 16 Produktionsstandorten für IV-Lösungen in Asien mit der nordamerikanischen Produktionsstätte von ICU Medical in Austin, Texas. Die Zusammenarbeit wird die Resilienz der Lieferkette verbessern und neue PVC-freie Technologien auf den nordamerikanischen Markt bringen. ICU Medical wird kommerzielle Dienstleistungen für einen reibungslosen Betrieb bereitstellen.
- Creation of one of the largest global IV solutions manufacturing networks with 1.4 billion annual units capacity
- Enhanced supply chain resiliency through combined 16 Asian production sites and North American facility
- Introduction of new PVC-free technologies to North American market
- Increased market stability and customer choice in North American IV solutions market
- None.
Insights
ICU Medical and Otsuka's joint venture creates massive IV solutions network with 1.4B unit capacity, combining North American presence with Asian manufacturing strength.
The formation of Otsuka ICU Medical LLC represents a strategic repositioning in the IV solutions market, combining ICU Medical's North American commercial strength with Otsuka's extensive Asian manufacturing network. The joint venture will command significant production capacity—approximately 1.4 billion annual units—through integration of ICU's Austin facility with Otsuka's 16 IV production sites across Asia.
This partnership addresses two key market needs: enhanced supply chain resiliency and innovation through PVC-free technologies in North America. The structure maintains continuity for customers, with ICU Medical providing commercial services for the joint venture, suggesting minimal disruption to existing relationships while expanding manufacturing capabilities.
For ICU Medical, this partnership provides access to Otsuka's substantial manufacturing scale and technological expertise. For Otsuka, it creates an established pathway into the North American market through ICU's commercial infrastructure and customer relationships.
The joint venture emerges amid heightened awareness of medical supply chain vulnerabilities that have affected healthcare systems. By diversifying manufacturing geographically, the partnership creates redundancies that could help insulate North American customers from regional supply disruptions.
The newly formed Otsuka ICU Medical LLC establishes a globally diversified manufacturing network that directly addresses supply chain resilience concerns in the critical IV solutions market. With
This diversification strategy represents a sophisticated approach to mitigating supply risk. By connecting ICU Medical's Texas production facility with Otsuka's 16 manufacturing sites across Asia, the joint venture creates multiple sourcing pathways that reduce vulnerability to regional disruptions—a key consideration for healthcare providers following recent global supply challenges.
The operational structure maintains stability by preserving ICU Medical as the commercial interface for North American customers while substantially expanding the manufacturing infrastructure. This arrangement balances relationship continuity with enhanced production capacity.
Beyond scale advantages, the introduction of PVC-free technologies suggests product innovation alongside supply chain enhancement. This technological component adds a differentiation element to what might otherwise be viewed as primarily a supply security initiative.
This cross-border manufacturing alliance demonstrates how complementary geographic strengths can create network resilience that neither partner could establish independently, while leveraging each company's core capabilities in their respective areas of expertise.
The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market.
"We are pleased to have successfully completed the formation of this joint venture with ICU Medical," said Shuichi Takagi, President and Representative Director of OPF. "Together, we look forward to bringing innovative IV solutions technologies to the North American market."
Vivek Jain, Chief Executive Officer at ICU Medical, commented, "This partnership will bring additional stability and choice to the North American IV solutions market, and we look forward to providing customers increased economic and clinical value."
Otsuka ICU Medical LLC combines OPF's expertise and global manufacturing scale—spanning 16 separate IV solutions production sites across Asia—with ICU Medical's strong North American production in
Investor Contacts:
Brian Bonnell, ICU Medical, Inc.
949-366-2183
John Mills, ICR, Inc.
646-277-1254
John.Mills@icrinc.com
Media Contact:
Harrison
949-366-4261
Harrison.Richards@icumed.com
About Otsuka Holdings Co., Ltd.: The corporate philosophy of Otsuka is "Otsuka-people creating new products for better health worldwide." The Otsuka group of companies, whose origins date back to 1921, strives daily to achieve the philosophy by creating innovative products, improving human health, and contributing to the lives of people worldwide. Otsuka has over 34,000 employees across 168 group companies in 32 countries and regions.
About Otsuka Pharmaceutical Factory, Inc. (OPF): OPF is the original company from which the Otsuka Group has grown. The management vision of OPF is "the best partner in clinical nutrition", and as a leading company in clinical nutrition in
About ICU Medical: ICU Medical Inc. (Nasdaq: ICUI) offers clinically essential medical devices that connect patients and caregivers through life-enhancing, innovative technology, and services that provide meaningful clinical value. The organization's robust portfolio features medical delivery systems and consumable products for infusion therapy, emergency medicine, general and regional anesthesia, home care, NICU/PICU, oncology, pain management, and respiratory care. More information about ICU Medical Inc. can be found at www.icumed.com.
Cautionary Note on Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and may often be identified by the use of words such as "will", "may", "could", "should", "would,", "project", "believe", "anticipate", "expect", "plan", "estimate", "forecast", "potential", "intend", "continue", "target", "build", "expand" or the negative thereof or comparable terminology, and may include (without limitation) information regarding the company's expectations, goals or intentions regarding the future, including, but not limited to, the proposed joint venture between the company and Otsuka Pharmaceutical Factory America, Inc. ("Otsuka"), the expected timetable for completing the proposed transaction, benefits and synergies of the proposed transaction, future opportunities for the company and products and any other statements regarding the company's and the proposed joint venture's future operations, anticipated business levels, future earnings, planned activities, anticipated growth, market opportunities, strategies, competition, and other expectations and targets for future periods.
These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about the company and the proposed transaction and assumptions management believes are reasonable, all of which are subject to risks and uncertainties that could cause actual results and events to differ materially from those stated in the forward-looking statements. These risks and uncertainties include, but are not limited to, the parties' ability to consummate the transaction, including Otsuka's ability to terminate the transaction under certain conditions; the regulatory approvals required for the transaction not being obtained, or not being obtained on the terms expected or on the anticipated schedule; the other conditions to the completion of the transaction not being obtained; decreased demand for the products of the company or the proposed joint venture; decreased free cash flow; the inability to recapture conversion delays or part/resource shortages on anticipated timing, or at all; changes in product mix; increased competition from competitors; lack of continued growth or improving efficiencies; unexpected changes in the company's arrangements with its largest customers; the parties' ability to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction; changes in relevant tax and other laws; inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements, and the providing of estimates of financial measures, in accordance with GAAP and related standards or on an adjusted basis; the completion of the joint venture being more difficult, time-consuming or costly than expected; operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the transaction; the retention of certain key employees of the business being difficult; the company's and the proposed joint venture business's expected or targeted future financial and operating performance and results; the scope, timing and outcome of any ongoing legal proceedings and the impact of any such proceedings on the company's and the proposed joint venture business's consolidated financial condition, results of operations or cash flows; the company's and the proposed joint venture business's ability to protect their intellectual property and preserve their intellectual property rights; the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the company's business or the proposed joint venture's business; uncertainties and matters beyond the control of management; and the possibility that the company may be unable to achieve expected synergies and operating efficiencies in connection with the transaction within the expected time-frames or at all.
For more detailed information on the risks and uncertainties associated with the company's business activities, see the risks described in the company's Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the "SEC") and in any subsequent filings with the SEC. You can access the company's Form 10-K and other filings through the SEC website at www.sec.gov, and the company strongly encourages you to do so. The company undertakes no obligation to update any statements herein for revisions or changes after the date of this communication.
View original content to download multimedia:https://www.prnewswire.com/news-releases/icu-medical-inc-and-otsuka-pharmaceutical-factory-inc-complete-joint-venture-to-bolster-iv-solutions-manufacturing-and-innovation-in-north-america-302444024.html
SOURCE ICU Medical, Inc.
FAQ
What is the purpose of the ICU Medical and Otsuka joint venture?
How many production sites does the ICUI-Otsuka joint venture have?
What new technology will the ICUI-Otsuka joint venture bring to North America?
Who will handle the commercial operations for the ICUI-Otsuka joint venture in North America?
